Key terms
About TBIO
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TBIO news
Apr 18
9:13am ET
Telesis Bio Leadership Shake-Up and Board Expansion
Apr 18
9:03am ET
Telesis Bio announces strategic focus on Gibson SOLA EDS platform
Feb 27
10:20am ET
Analysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 26
9:18am ET
Telesis Bio sees Q4 revenue $7M vs. $9.5M last year
No recent press releases are available for TBIO
TBIO Financials
Key terms
Ad Feedback
TBIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TBIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range